Stock

BioNTech SE (BNTX)

NASDAQ · Healthcare · Biotechnology

Profile

BioNTech SE

BioNTech SE logo
Exchange
NASDAQ
Ticker
BNTX
Sector
Healthcare
Industry
Biotechnology
Country
DE

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

Key facts

BioNTech SE: key facts

  • BioNTech SE (NASDAQ: BNTX) is a Biotechnology company in the Healthcare sector.
  • In fiscal 2025, BioNTech SE reported revenue of 2.8B EUR and net income of -1.1B EUR.
  • Revenue fell 38.3% a year over the last 4 fiscal years.
  • Free cash flow was positive in 4 of the last 5 fiscal years.
  • Net income was positive in 3 of the last 5 fiscal years.
  • Over the last twelve months, revenue was 2.4B EUR and net income was -1.5B EUR.

MonkScore

BioNTech SE's MonkScore

MonkScore

MonkScore range: 30–39

as of November 2026

Sector rank: 465 of 630 in Healthcare

How this score is madeDisclaimer

Pillar ranges

  • Growth20–29
  • Profitability40–49
  • Quality90–100
  • Market Conviction10–19
  • Safety80–89

The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–9 to 90–100.

Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.

Fundamentals

Figures from the statements

BioNTech SE's annual figures and the last twelve months, in EUR. Last report: 30 September 2026.

FigureLast 12 monthsFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue2.4B EUR2.8B EUR2.8B EUR3.8B EUR17.3B EUR19.0B EUR
Gross profit1.7B EUR2.1B EUR2.2B EUR3.2B EUR14.3B EUR16.1B EUR
Operating income-1.7B EUR-623.9M EUR-1.3B EUR690.4M EUR12.6B EUR15.3B EUR
Net income-1.5B EUR-1.1B EUR-665.3M EUR930.3M EUR9.4B EUR10.3B EUR
Operating cash flow-247.6M EUR438.0M EUR207.7M EUR5.4B EUR13.6B EUR889.7M EUR
Capital expenditure-208.6M EUR-168.2M EUR-452.3M EUR-705.5M EUR-363.3M EUR-154.0M EUR
Free cash flow-456.2M EUR269.8M EUR-244.6M EUR4.7B EUR13.2B EUR735.7M EUR
Total debt359.8M EUR267.3M EUR254.2M EUR219.1M EUR212.2M EUR301.5M EUR
Cash10.2B EUR7.7B EUR9.8B EUR11.7B EUR13.9B EUR1.7B EUR

Revenue growth a year

1-year
0.2%
3-year
-45.8%
4-year
-38.3%

Compound growth between fiscal years.

Peers

Similar companies

  • SK bioscience Co.,Ltd.KRX:302440MonkScore range: 30–39
  • Bavarian Nordic A/SCPH:BAVAMonkScore range: 30–39
  • Neuren Pharmaceuticals LimitedASX:NEUMonkScore range: 30–39
  • Keymed Biosciences Inc.HKG:2162MonkScore range: 40–49
  • Egetis Therapeutics AB (publ)STO:EGTXMonkScore range: 40–49
  • 3SBio Inc.HKG:1530MonkScore range: 40–49
  • Inventiva S.A.EPA:IVAMonkScore range: 40–49
  • Immunocore Holdings plcNASDAQ:IMCRMonkScore range: 40–49
See the full analysisBioNTech SE's exact MonkScore and pillar scores, in the MonkStreet app

Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click

MonkStreet provides research, not investment advice.

Page built on 8 November 2026.